Curative Biotechnology, Inc. CUBT
0.81 USD 0.00 (+0.00%)
At closeNov 12, 2026, 4:00 PM EST
0.675 Day range 0.85
0.031 52-week range 1.99
- YTD
- -0.59%
- 1 year
- -2.04%
News
globenewswire.com Curative Biotechnology, Inc. Issues Letter to Shareholders Company Reviews Significant Ophthalmology, Intellectual Property and Translational Development Milestones Achieved Over the Past Year Palm Beach Gardens, FL, Sept. 11, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- Curative…
globenewswire.com Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the…
globenewswire.com Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the…
globenewswire.com Curative Biotechnology Announces Canadian Patent Allowance “Druggable Target to Treat Retinal Degeneration” Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing…
globenewswire.com Curative Biotechnology, Inc. Announces Letter to Shareholders Strategic Update and New Path to Value Creation Palm Beach Gardens, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a…
globenewswire.com Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor Palm Beach Gardens, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel…
headlinesoftoday.com Curative Biotechnology, Inc. Announces Nomination of Dr. Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company…
globenewswire.com Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company…
headlinesoftoday.com Curative Biotechnology, Inc. Announces Nomination of Dr. Palm Beach Gardens, FL, March 22, 2024 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel…
globenewswire.com Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors Palm Beach Gardens, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel…
globenewswire.com Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange
globenewswire.com Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange
globenewswire.com CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients , Late-Stage Rabies Therapeutic and Age-related Macular Degeneration
globenewswire.com CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies
prnewswire.com Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the Company has reached agreement with Mid-Atlantic…
globenewswire.com Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Exper tise in Neurobiology